ArticleBMC microbiology2025
The in vitro evaluation of synergistic effects of ciprofloxacin and berberine hydrochloride against Pseudomonas aeruginosa.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In vitro antibiofilm activity of dermcidin derived peptides against Pseudomonas aeruginosa and Staphylococcus aureus pathogens.Molecular biology reports · 2026Article
- Inhibitory effects of Quercetagetin on the growth, biofilm formation, and virulence factors of bovine mastitis-associatedFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPseudomonas aeruginosa is a major cause of severe infections, leading to significant morbidity and mortality rates due to its ability of biofilm formation and antibiotic resistance. This study evaluates the in vitro antimicrobial and antibiofilm effects of ciprofloxacin and berberine hydrochloride, alone and in combination, against clinical and standard strains of P. aeruginosa.
methodsClinical isolates of carbapenem-susceptible P. aeruginosa (CSPA), carbapenem-resistant P. aeruginosa (CRPA), and the standard P. aeruginosa PAO
resultsThe minimum inhibitory concentrations (MICs) of ciprofloxacin and berberine hydrochloride ranged from 0.5 to 64 µg/mL and 593 to 1187 µg/mL, respectively. The minimum bactericidal concentrations (MBCs) for both agents were ≥ 2× MIC. Neither ciprofloxacin nor berberine hydrochloride was able to eradicate 24-hour preformed biofilms (MBEC). However, biofilm prevention (MBIC) occurred at sub-MIC levels (0.5-1× MIC). The combination of ciprofloxacin and berberine hydrochloride demonstrated synergistic activity against PAO
conclusionBerberine hydrochloride may serve as a promising synergistic agent to enhance the antimicrobial and antibiofilm activity of ciprofloxacin in vitro. This combination warrants further exploration as a therapeutic strategy against resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.